摘要
微生态药物在许多复杂性和慢性疾病中显示出极大的潜力,逐渐成为国际制药行业的新趋势。基于科睿唯安旗下的Cortellis数据库,采用定量分析和专家智慧相结合的方法,从总体研发现状、主要国家/地区、主要适应症、重点企业研发管线、重点在研药物、商业化交易多个维度展现全球微生态药物的研发和商业化全景。分析结果显示:全球共有142个在研微生态药物,其中49个药物处于临床阶段。美国在微生态药物研发和商业化方面遥遥领先,其数量占在研药物总量的70%。在研药物的适应症主要集中于炎症性肠病、艰难梭菌感染、溃疡性结肠炎等肠道感染性疾病。4D pharma公司的在研药物数量最多,微生态药物重点研发企业均建立起核心技术平台。处于临床3期的微生态药物共有7个,全球微生态药物商业化交易共有303起,最大的交易金额是27.8亿美元。未来,微生态药物有望在更难被人类征服的肿瘤和神经系统疾病方面取得突破性进展。
In the recent years,numerous studies highlighted the potential role of microecological drugs in treating multiple diseases and preserving host’s health.In this paper,all the data was extracted from Clarivate via Cortellis.The results of qualitative analysis and expert wisdom were as follows.Up to data,142 kinds of microecological drugs have been identified and 49 kinds of them have been undergone clinical trials.The United States was far ahead of other countries with 70 percent of the amount in microecological drugs.The drug indications were focused on Clostridium difficile infection,inflammatory bowel disease and ulcerative colitis.The key players have established advanced experimental platforms for discovery and development of novel product candidates,while 4D pharma was a world leader in this field.There were seven drugs in phase 3 clinical development.Access to 303 microecological drugs deal records,the maximum transaction was$2.78 billion.In the future,microecological drugs may make a major breakthrough in cancer and nervous system diseases treatment.
作者
高倩
张宏翔
江洪
叶茂
GAO Qian;ZHANG Hong-xiang;JIANG Hong;YE Mao(Wuhan Library,Chinese Academy of Sciences,Wuhan 430071,China;National Science Library,Chinese Academy of Sciences,Beijing 100190,China;Chinese Society of Biotechnology,Beijing 100101,China)
出处
《中国生物工程杂志》
CAS
CSCD
北大核心
2020年第1期166-173,共8页
China Biotechnology
基金
湖北省技术创新专项(软科学研究类)(2018ADC003)
中科院服务山东创新发展建设研究(KFJ-STS-QYZX-054)资助项目.
关键词
微生态药物
临床研发
商业化交易
Microecological drugs
Clinical R&D
Commercial deal
